Amylyx Pharmaceuticals, Inc. (AMLX): R&D Expense
$90.40M
Year ended 2025-12-31
$92.45M
Trailing 12 months to 2026-06-30
-1.1%
3-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $90.40M | -13.1% | 2026-03-03, From 2025-01-01 |
| 2024-12-31 | $104.08M | -18.8% | 2026-03-03, From 2024-01-01 |
| 2023-12-31 | $128.19M | +37.2% | 2025-03-04, From 2023-01-01 |
| 2022-12-31 | $93.45M | +112.2% | 2024-02-22, From 2022-01-01 |
| 2021-12-31 | $44.04M | n/a | 2024-02-22, From 2021-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Amylyx Pharmaceuticals, Inc. (AMLX) | 2025-12-31 | $90.40M | -13.1% |
| Abbott Laboratories (ABT) | 2025-12-31 | $2.94B | +3.4% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $9.95B | -10.8% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $13.34B | +21.3% |
| Pfizer Inc (PFE) | 2025-12-31 | $10.44B | -3.6% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $14.66B | -14.9% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $1.90M | +11.8% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $15.79B | -12.0% |
| Provectus Biopharmaceuticals, Inc. (PVCT) | 2025-12-31 | $1.90M | -7.5% |
Compare AMLX, ABT, BMY, LLY side by side · Screen every company in Pharmaceutical Preparations ↗